Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...
After radiation therapy, certain cancer patients face a lingering question: Is a troubling lesion a return of the cancer, or ...
In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS ...
For the first time, researchers have used machine learning—a type of artificial intelligence (AI)—to identify the most ...
A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret ...
Analysis of Tumor Microenvironmental Features Between Primary and Synchronous Liver Metastases From Patients With Colorectal Cancers Using a Deep Learning Algorithm We identified a cohort of 1,201 ...
GSK licenses Noetik’s AI foundation models in anchor partnership to transform cancer therapeutic research and development ...
Researchers at the UNC School of Medicine and the UNC Eshelman School of Pharmacy have made a breakthrough that could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback